

46. The protein of claim 44 wherein the protein or variants thereof are post-translationally modified into a lipoprotein.

47. The protein of claim 45 wherein those proteins or protein fragments are lymphocyte T cell epitopes or lymphocyte T cell epitopes and lymphocyte B cell epitopes.

48. The protein of claim 45 wherein the lymphocyte T cell epitopes are highly immunogenic promiscuous T cell epitopes.

49. The protein of claim 45 wherein those proteins or protein fragments are lymphocyte B cell epitopes or lymphocyte B cell epitopes and lymphocyte T cell epitopes.

REMARKS

Applicants provisionally elect claims within the scope of Group IV for examination in this application.

The application has been amended to present only claims within the scope of Group IV. Certain claims have been cancelled without prejudice to the Applicants' right to file continuation applications that present claims within the scope of Groups I to VIII.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Richard J. Polley
Registration No. 28,107

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446